Get the latest news, insights, and market updates on TRVI (Trevi Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
How Trevi Therapeutics’ (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations
Trevi Therapeutics recently reported its third quarter earnings, highlighting a net loss of US$11.8 million and progress toward advancing its chronic cough drug Haduvio into Phase 3 clinical trials. The company has strengthened its cash position following a successful funding round and is actively engaging with the FDA to support pivotal trial design for multiple chronic cough indications. With its clinical pipeline moving closer to late-stage trials, we'll look at how upcoming regulatory... Nov 15, 2025 - $TRVI
Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension
Trevi Therapeutics (TRVI) has caught the attention of investors after recent updates on its chronic cough clinical programs. The company is moving ahead with Phase 3 plans for IPF-related chronic cough, supported by encouraging trial results and new funding. See our latest analysis for Trevi Therapeutics. After a remarkable year on the news front, Trevi Therapeutics has seen its share price climb an impressive 160.8% since January, while its total shareholder return tops 313% over the past... Nov 15, 2025 - $TRVI
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced financial results for the quarter ended September 30, 2025, and provided business updates. Nov 13, 2025 - $TRVI
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, November 13, 2025, at 4:30 p.m. ET, to provide a corporate update and Nov 6, 2025 - $TRVI
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and James Cassella, Ph.D., Chief Development Officer, will participate in a fireside chat at the S Nov 4, 2025 - $TRVI
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the acceptance of two abstracts for presentation at the CHEST 2025 Annual Meeting, to be held from October 19 to 22 in Chicago, Illinois. The key safety and efficacy re Oct 8, 2025 - $TRVI
Trevi Therapeutics (TRVI): Assessing Valuation as RIVER Trial Data Prepares for Major Scientific Debut
If you are considering what to do next with Trevi Therapeutics (TRVI), you’re in good company. The company’s announcement that its Phase 2a RIVER trial data for Haduvio will be highlighted in two poster presentations at the European Respiratory Society Congress is more than a blip on the radar. Focused on refractory chronic cough, a condition with urgent unmet need and no current FDA-approved treatments, the upcoming data release has quickly turned heads and put Trevi’s pipeline in the... Sep 23, 2025 - $TRVI
How Investors May Respond To Trevi Therapeutics (TRVI) Highlighting RIVER Trial Data at ERS 2025
Trevi Therapeutics announced that data from its Phase 2a RIVER trial of Haduvio™ (oral nalbuphine ER) for refractory chronic cough will be featured in two poster presentations at the European Respiratory Society Congress 2025 in Amsterdam. This brings scientific and investor focus to the company’s approach for a condition with significant unmet medical need and no FDA-approved therapies. We’ll explore how the upcoming medical congress presentations support Trevi’s positioning in the... Sep 20, 2025 - $TRVI
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that data from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC, will be highlighted in two poster presentations at the Europ Sep 18, 2025 - $TRVI
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple